Skip to main content

This website contains promotional content and is intended for Healthcare Professionals based in the United Kingdom only. Some content is only relevant to HCPs practising in Great Britain (England, Scotland, Wales).

Evolving role of AI in the diagnosis of Fabry disease

Recognition of pre-hypertrophic cardiac involvement in Fabry disease using automated ECGs

An analysis comparing ECGs from 1496 healthy individuals to 142 patients with Fabry disease (without LVH) identified nine ECG parameters that were significantly different between the groups and could be useful for the purpose of screening the very early stages of cardiomyopathy in Fabry disease.¹

Click the buttons below to explore the parameters that match with the letters on the ECG.

Clinical progression and patient outcomes

Download a helpful schematic of clinical manifestations, laboratory findings, cardiac imaging / ECG results that may be suggestive of Fabry disease.

DOWNLOAD

ECG, electrocardiogram; LVH, left ventricular hypertrophy

Namdar M, et al. Int J Cardiol. 2021;338:121–6.

MAT-XU-2300310 (v1.0)
Date of preparation: March 2023

YOU ARE NOW LEAVING THE SANOFI CAMPUS UK WEBSITE

You are going to a website that is not operated by Sanofi. Sanofi has no control over the content or availability of linked sites or resources, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them. Please ensure that you read the legal and privacy policy sections of any third-party site to which you link.

Continue

Welcome to Sanofi Campus UK

This site is intended for UK healthcare professionals only and contains information on Sanofi UK’s medicines, educational resources and more. Please click the appropriate button below. By entering this site, you are confirming that you are a UK healthcare professional. This site contains promotional information. Please note that some of the content on the website is only relevant for HCPs practising in Great Britain (England, Scotland, Wales).

MAT-XU-2300297 (v1.0)
Date of Preparation: February 2023

P wave morphology in the precordial lead V3
(categorical classification: 1=single upright, −1=single inverted, 2=biphasic, leading positive, −2=biphasic, leading negative)

Amplitude of the positive component of the P wave in lead DI
(P+ Amp I, μV)

P wave area in the precordial lead V1
(P Area V1, μV-milliseconds [μV. ms], defined as the algebraic sum of both the positive and negative areas or either alone if the P wave is not biphasic)

QT dispersion (ms)
defined as the difference between the shortest and longest QT interval in the 12 lead ECG

4/8 QRS
(time-normalized QRS spatial velocity at 4/8 of the total QRS duration, μV/ms)

QT dispersion (ms)
defined as the difference between the shortest and longest QT interval in the 12 lead ECG

4/8 QRS
(time-normalized QRS spatial velocity at 4/8 of the total QRS duration, μV/ms)

Amplitude of the ST segment in the precordial lead V2
(ST60 Amp V2, μV)

Duration of the S wave in the precordial lead V1
(S Dur V1; ms)

Amplitude of the ST segment in the precordial lead V2
(ST60 Amp V2, μV)

QT dispersion (ms)
defined as the difference between the shortest and longest QT interval in the 12 lead ECG

Left ventricular hypertrophy (LVH) Score
(derived from an age and sex based modified Romhilt-Estes score, dimensionless)